STOK

AI Memo

Stoke Therapeutics

As of 2026-09-24/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-24 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

FDA pre-NDA meeting for zorevunersen • 2026-12-31

Base target: $26 / p=55% prob

Biggest risk

Value remains concentrated in an unapproved Dravet program. An unfavorable pivotal readout, regulatory disagreement, delay or greater spending could overwhelm the secondary pipeline's early-stage optionality.

Invalidation

Break below $12 or thesis failure.

What would change my mind?

Completed EMPEROR enrollment, the planned regulatory path, and approximately $420 million of cash, cash equivalents and marketable securities after a subsequent ATM sale support progress toward a potential early-2028 U.S. launch [#SEC-8K-2026-08-03]. Successful pivotal data would materially strengthen the case.

Research note

Recommendation

—

Confidence

medium

As of

2026-09-24

Base target

$26

p=55%

Bull target

$48

p=20%

Bear target

$12

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

STK-002 OSPREY initial data
Phase 3 EMPEROR readout
Completed EMPEROR enrollment, the planned regulatory path, and approximately $420 million of cash, cash equivalents and marketable securities after a subsequent ATM sale support progress toward a potential early-2028 U.S.

BearKey bullets

EMPEROR's Q3 2027 readout is binary; enrollment completion and open-label observations do not establish Phase 3 efficacy [#SEC-8K-2026-08-03].
STK-002 remains in Phase 1 dose escalation, limiting its ability to offset a zorevunersen setback [#SEC-8K-2026-08-03].
The pre-NDA meeting and rolling submission are planned milestones, not FDA agreement or approval [#SEC-8K-2026-08-03].

WatchKey bullets

FDA pre-NDA meeting for zorevunersen

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $26 (p=55%)

Target spread vs base: +85% / -54%

Scenario probabilities

Bull Target: $48 (p=20%)Base Target: $26 (p=55%)Bear Target: $12 (p=25%)

Commentary

The packet contains two recent company-news headlines but no usable social, options, short-interest or measured news-sentiment series; the zero-valued sentiment fields are unavailable-data placeholders, not observed readings. No supported post-release price reaction or analyst revision is available. The deterministic prior is neutral despite strong primary-source coverage, so the view remains milestone-focused rather than a near-term momentum call.

As of 2026-09-24 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

STK-002 OSPREY initial data
Phase 3 EMPEROR readout

Scenarios

Bull Target (Scenario probability)

$48 / p=20% prob

Base Target (Scenario probability)

$26 / p=55% prob

Bear Target (Scenario probability)

$12 / p=25% prob

Analysis 2026-09-24 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
FDA pre-NDA meeting for zorevunersen
Stoke plans a pre-NDA meeting in H2 2026 to discuss the proposed data package and statistical analysis plan. The August 3 filing is documented in [#8-K-2026-08-03]; the company's results exhibit supplies the meeting details [#SEC-8K-2026-08-03]. A constructive update could reduce submission uncertainty, but a meeting is not an approval.
Prob 70.00% • Move 8.00% • Priced-in 40.00%
EVENT2027-03-31
Planned rolling U.S. NDA initiation
Management plans to begin a rolling zorevunersen NDA submission in Q1 2027 and complete it in H2 2027, subject to the remaining clinical data and regulatory work [#SEC-8K-2026-08-03].
Prob 65.00% • Move 12.00% • Priced-in 45.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

STK-002 OSPREY initial data
2027-06-30
Dose escalation is underway in the Phase 1 OSPREY study in autosomal dominant optic atrophy; Stoke anticipates initial safety and efficacy data in H1 2027 [#SEC-8K-2026-08-03]. Early-stage data may be difficult to interpret.
Prob 60% • Move 15% • Priced-in 20%
Phase 3 EMPEROR readout
2027-09-30
The 162-patient primary U.S. analysis cohort has completed enrollment. Stoke anticipates a Q3 2027 readout measuring change in major motor seizure frequency; those data are expected to complete the planned U.S. NDA [#SEC-8K-2026-08-03]. This is the dominant binary value driver.
Prob 60% • Move 45% • Priced-in 30%

Risks

EMPEROR's Q3 2027 readout is binary; enrollment completion and open-label observations do not establish Phase 3 efficacy [#SEC-8K-2026-08-03].
STK-002 remains in Phase 1 dose escalation, limiting its ability to offset a zorevunersen setback [#SEC-8K-2026-08-03].
The pre-NDA meeting and rolling submission are planned milestones, not FDA agreement or approval [#SEC-8K-2026-08-03].
The reported approximately $420 million funding position includes $65.7 million from a subsequent ATM sale; additional financing or higher spending could dilute holders or shorten runway [#SEC-8K-2026-08-03].

Peers

Symbol	Summary
AUPH	Similar market capitalization but commercially oriented; a contrast for launch execution rather than a direct zorevunersen peer.
GHRS	Clinical-stage neuroscience comparator, but a different modality and indication; useful for development-stage risk, not a direct Dravet valuation multiple.
NBTX	Similarly sized clinical-stage biotech, but oncology exposure makes its clinical and commercial economics a loose comparison.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-24